{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:52:00Z","timestamp":1768643520171,"version":"3.49.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2019087"],"award-info":[{"award-number":["2019087"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.eprac.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T13:01:04Z","timestamp":1666270864000},"page":"484-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Personalized Treatment of Patients With Primary Aldosteronism"],"prefix":"10.1016","volume":"29","author":[{"given":"Hiba","family":"Obeid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley M.","family":"Chen Cardenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafaq","family":"Khairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-6190","authenticated-orcid":false,"given":"Adina F.","family":"Turcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.eprac.2022.10.008_bib1","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans : a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension: a cohort study","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"issue":"14","key":"10.1016\/j.eprac.2022.10.008_bib4","article-title":"Primary aldosteronism screening rates differ with sex, race, and comorbidities","volume":"11","author":"Turcu","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib5","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.surg.2018.05.085","article-title":"Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives","volume":"165","author":"Ruhle","year":"2019","journal-title":"Surgery"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib7","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/HJH.0000000000001088","article-title":"Guidelines for primary aldosteronism: uptake by primary care physicians in Europe","volume":"34","author":"Mulatero","year":"2016","journal-title":"J\u00a0Hypertens"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.008_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamasurg.2021.0254","article-title":"Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism","volume":"156","author":"Liu","year":"2021","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.surg.2019.05.087","article-title":"Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system","volume":"167","author":"Sivarajah","year":"2020","journal-title":"Surgery"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.008_bib10","doi-asserted-by":"crossref","first-page":"e3603","DOI":"10.1210\/clinem\/dgab327","article-title":"Increasing incidence of primary aldosteronism in western Sweden during 3 decades - yet an underdiagnosed disorder","volume":"106","author":"Gkaniatsa","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism - a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.10.008_bib15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.008_bib17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/HYPERTENSIONAHA.118.11382","article-title":"Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism","volume":"72","author":"Williams","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.5842","article-title":"Clinical outcomes after unilateral adrenalectomy for primary aldosteronism","volume":"154","author":"Vorselaars","year":"2019","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.008_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","article-title":"Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial","volume":"4","author":"Dekkers","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.008_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib22","first-page":"69","article-title":"Approach to the surgical management of primary aldosteronism","volume":"4","author":"Iacobone","year":"2015","journal-title":"Gland Surg"},{"key":"10.1016\/j.eprac.2022.10.008_bib23","article-title":"Long term outcome of aldosteronism after target treatments","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-8587(20)30314-4","article-title":"Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study","volume":"8","author":"Ebbehoj","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.008_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/cen.13442","article-title":"Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism","volume":"87","author":"Nanba","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib26","first-page":"1182","article-title":"Histopathological classification of cross-sectional image-negative hyperaldosteronism","volume":"102","author":"Yamazaki","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"39","key":"10.1016\/j.eprac.2022.10.008_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004986","article-title":"Comparison between adrenal venous sampling and computed tomography in the diagnosis of primary aldosteronism and in the guidance of adrenalectomy","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.eprac.2022.10.008_bib28","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1210\/jc.2013-4146","article-title":"Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism","volume":"99","author":"Lim","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.008_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-151-5-200909010-00007","article-title":"Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism","volume":"151","author":"Kempers","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jamcollsurg.2010.05.006","article-title":"Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease","volume":"211","author":"Mathur","year":"2010","journal-title":"J\u00a0Am Coll Surg"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.008_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/cen.13582","article-title":"Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism","volume":"88","author":"Umakoshi","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.008_bib32","doi-asserted-by":"crossref","first-page":"e3628","DOI":"10.1210\/clinem\/dgaa482","article-title":"The concordance between imaging and adrenal vein sampling varies with aldosterone-driver somatic mutation","volume":"105","author":"Wannachalee","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/HYPERTENSIONAHA.121.18284","article-title":"Feasibility of imaging-guided adrenalectomy in young patients with primary aldosteronism","volume":"79","author":"Rossi","year":"2022","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.008_bib34","doi-asserted-by":"crossref","first-page":"e2087","DOI":"10.1210\/clinem\/dgab047","article-title":"Adrenal venous sampling in young patients with primary aldosteronism. Extravagance or irreplaceable?","volume":"106","author":"Gkaniatsa","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.10.008_bib35","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1148\/rg.25si055514","article-title":"Adrenal vein sampling: how to make it quick, easy, and successful","volume":"25","author":"Daunt","year":"2005","journal-title":"Radiogrpahics"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2265.2008.03450.x","article-title":"What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?","volume":"70","author":"Young","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.008_bib37","first-page":"89","article-title":"Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures","volume":"24","author":"Jakobsson","year":"2018","journal-title":"Diagn Interv Radiol"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib38","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1210\/clinem\/dgaa952","article-title":"Approach to the patient with primary aldosteronism: utility and limitations of adrenal vein sampling","volume":"106","author":"Turcu","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2022.10.008_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib40","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jc.2019-00996","article-title":"Adrenal insufficiency after unilateral adrenalectomy in primary aldosteronism: long-term outcome and clinical impact","volume":"104","author":"Heinrich","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.008_bib41","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1210\/jc.2012-1917","article-title":"A\u00a0clinical prediction score to diagnose unilateral primary aldosteronism","volume":"97","author":"K\u00fcpers","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib42","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/HJH.0000000000001855","article-title":"Development and validation of subtype prediction scores for the workup of primary aldosteronism","volume":"36","author":"Kobayashi","year":"2018","journal-title":"J\u00a0Hypertens"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.008_bib43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/EJE-20-0656","article-title":"Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful","volume":"183","author":"Burrello","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","article-title":"Primary aldosteronism: factors associated with normalization of blood pressure after surgery","volume":"135","author":"Sawka","year":"2001","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib45","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1210\/js.2019-00295","article-title":"Predictors of clinical success after surgery for primary aldosteronism in the Japanese nationwide cohort","volume":"3","author":"Morisaki","year":"2019","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.eprac.2022.10.008_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.925591","article-title":"Predictive factors of clinical success after adrenalectomy in primary aldosteronism: a systematic review and meta-analysis","volume":"13","author":"Manosroi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/ajh\/hpab195","article-title":"External validation of clinical prediction models in unilateral primary aldosteronism","volume":"35","author":"Sam","year":"2022","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.008_bib49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","article-title":"Targeting CXCR4 (CXC chemokine receptor type 4) for molecular imaging of aldosterone-producing adenoma","volume":"71","author":"Heinze","year":"2018","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.eprac.2022.10.008_bib50","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1021\/acs.jmedchem.1c00539","article-title":"Development of [18F]AldoView as the first highly selective aldosterone synthase PET tracer for imaging of primary hyperaldosteronism","volume":"64","author":"Sander","year":"2021","journal-title":"J\u00a0Med Chem"},{"issue":"12","key":"10.1016\/j.eprac.2022.10.008_bib51","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1210\/jc.2019-01182","article-title":"Three discrete patterns of primary aldosteronism lateralization in response to cosyntropin during adrenal vein sampling","volume":"104","author":"Wannachalee","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/HYPERTENSIONAHA.119.13866","article-title":"Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping","volume":"75","author":"Turcu","year":"2020","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.008_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16209","article-title":"Use of steroid profiling combined with machine learning for identification and subtype classification in primary aldosteronism","volume":"3","author":"Eisenhofer","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.eprac.2022.10.008_bib54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","article-title":"Primary aldosteronism: practical approach to diagnosis and management","volume":"138","author":"Byrd","year":"2018","journal-title":"Circulation"},{"issue":"10008","key":"10.1016\/j.eprac.2022.10.008_bib55","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib56","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib57","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.eprac.2022.10.008_bib58","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/EJE-19-0215","article-title":"Therapy of endocrine disease: medical treatment of primary aldosteronism","volume":"181","author":"Lechner","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.008_bib59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/jc.2018-01299","article-title":"Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism","volume":"104","author":"Nanba","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.10.008_bib60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","article-title":"Pharmacological treatment of aldosterone excess","volume":"154","author":"Deinum","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.008_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.008_bib62","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib63","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.119.13131","article-title":"Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function","volume":"74","author":"Kobayashi","year":"2019","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib64","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jch.12914","article-title":"Effects of treating primary aldosteronism on renal function","volume":"19","author":"Kramers","year":"2017","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.008_bib65","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/jc.2013-2180","article-title":"Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases","volume":"99","author":"Iwakura","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.008_bib66","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.008_bib67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ando.2016.04.009","article-title":"Primary aldosteronism and pregnancy","volume":"77","author":"Landau","year":"2016","journal-title":"Ann Endocrinol (Paris)"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib68","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","volume":"80","author":"Liszewski","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.eprac.2022.10.008_bib69","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.eprac.2022.10.008_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxlet.2019.08.003","article-title":"The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism","volume":"315","author":"McGraw","year":"2019","journal-title":"Toxicol Lett"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000199905","article-title":"Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy","volume":"44","author":"Andriulli","year":"1989","journal-title":"Digestion"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.008_bib74","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1007\/s12325-022-02282-3","article-title":"Antihypertensive effect of long-term monotherapy with esaxerenone in patients with essential hypertension: relationship between baseline urinary sodium excretion and its antihypertensive effect","volume":"39","author":"Ichikawa","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib75","article-title":"Amiloride: a review","volume":"21","author":"Sun","year":"2020","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2125.1984.tb02478.x","article-title":"Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects","volume":"18","author":"Millar","year":"1984","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib77","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.1980.75","article-title":"Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients","volume":"27","author":"Ramsay","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.008_bib78","first-page":"94","article-title":"New drug evaluations amiloride (Midamor, Merck, Sharp and Dohme)","volume":"15","author":"Macfie","year":"1981","journal-title":"Drug Intell Clin Pharm"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/clpt.1985.176","article-title":"Oral triamterene disposition","volume":"38","author":"S\u00f6rgel","year":"1985","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11606-015-3469-1","article-title":"Triamterene enhances the blood pressure lowering effect of hydrochlorothiazide in patients with hypertension","volume":"31","author":"Tu","year":"2016","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.eprac.2022.10.008_bib81","unstructured":"Niyazov R, Sharman T. Triamterene. StatPearls."},{"issue":"6812","key":"10.1016\/j.eprac.2022.10.008_bib82","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/bmj.303.6812.1217","article-title":"Does triamterene cause renal calculi?","volume":"303","author":"Woolfson","year":"1991","journal-title":"Br Med J"},{"issue":"21","key":"10.1016\/j.eprac.2022.10.008_bib83","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1001\/jama.1980.03310210045027","article-title":"Triamterene nephrolithiasis","volume":"244","author":"Ettinger","year":"1980","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.eprac.2022.10.008_bib84","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41574-020-0382-4","article-title":"Pathogenesis and treatment of primary aldosteronism","volume":"16","author":"Zennaro","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"36","key":"10.1016\/j.eprac.2022.10.008_bib85","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib86","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"31","key":"10.1016\/j.eprac.2022.10.008_bib87","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib88","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"15","key":"10.1016\/j.eprac.2022.10.008_bib89","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.eprac.2022.10.008_bib90","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2022.10.008_bib91","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.008_bib92","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.eprac.2022.10.008_bib93","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/acs.jmedchem.2c00402","article-title":"Discovery of apararenone (MT-3995) as a highly selective, potent, and novel nonsteroidal mineralocorticoid receptor antagonist","volume":"65","author":"Iijima","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.eprac.2022.10.008_bib94","unstructured":"Baxdrostat (CIN-107). CINCOR. Accessed October 9, 2017. https:\/\/www.cincor.com\/cin-107"},{"issue":"6","key":"10.1016\/j.eprac.2022.10.008_bib95","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/HYPERTENSIONAHA.117.10226","article-title":"Macrolides blunt aldosterone biosynthesis: a proof-of-concept study in KCNJ5 mutated adenoma cells ex\u00a0vivo","volume":"70","author":"Caroccia","year":"2017","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib96","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/en.2013-1944","article-title":"Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas","volume":"155","author":"Tauber","year":"2014","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.eprac.2022.10.008_bib97","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0889-8529(18)30098-7","article-title":"Glucocorticoid-remediable aldosteronism","volume":"23","author":"Dluhy","year":"1994","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.eprac.2022.10.008_bib98","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/HYPERTENSIONAHA.116.07615","article-title":"Dietary salt intake is a determinant of cardiac changes after treatment of primary aldosteronism: a prospective study","volume":"68","author":"Catena","year":"2016","journal-title":"Hypertension"},{"issue":"24","key":"10.1016\/j.eprac.2022.10.008_bib99","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1161\/CIR.0b013e318279acbf","article-title":"Sodium, blood pressure, and cardiovascular disease: Further evidence supporting the American Heart Association sodium reduction recommendations","volume":"126","author":"Whelton","year":"2012","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.eprac.2022.10.008_bib100","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/nu13093232","article-title":"Sodium intake and health: what should we recommend based on the current evidence?","volume":"13","author":"Mente","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.eprac.2022.10.008_bib101","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1161\/HYPERTENSIONAHA.120.16440","article-title":"Altered taste perception for sodium chloride in patients with primary aldosteronism: a prospective cohort study","volume":"77","author":"Adolf","year":"2021","journal-title":"Hypertension"},{"issue":"19 I","key":"10.1016\/j.eprac.2022.10.008_bib102","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1073\/pnas.80.19.6136","article-title":"Amiloride reduces the taste intensity of Na+ and Li+ salts and sweeteners","volume":"80","author":"Schiffman","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.eprac.2022.10.008_bib103","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1210\/clinem\/dgz051","article-title":"Patients with primary aldosteronism respond to unilateral adrenalectomy with long-term reduction in salt intake","volume":"105","author":"Adolf","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5816","key":"10.1016\/j.eprac.2022.10.008_bib104","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.2.5816.729","article-title":"Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin","volume":"2","author":"Brown","year":"1972","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.eprac.2022.10.008_bib105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eprac.2022.10.008_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.625457","article-title":"Real-world effectiveness of mineralocorticoid receptor antagonists in primary aldosteronism","volume":"12","author":"Tezuka","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22006498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:14:23Z","timestamp":1761516863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22006498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1530891X22006498"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.10.008","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Treatment of Patients With Primary Aldosteronism","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}